Navigation Links
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension

xercise Capacity and Dyspnea in WHO Functional Class II and Class III Patients with Pulmonary Arterial Hypertension" will be presented on Wednesday, May 23 by Horst Olschewski, MD, Professor of Medicine in the Division of Pulmonology at the Medical University of Graz in Graz, Austria.

About Ambrisentan

Ambrisentan is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor. Activation of the ETA receptor by endothelin, a small peptide hormone, leads to vasoconstriction (narrowing of blood vessels) and cell proliferation. PAH is associated with elevated endothelin blood levels. Ambrisentan has been granted orphan drug designation for the treatment of PAH in both the United States and European Union.

The U.S. Food and Drug Administration (FDA) recently accepted for filing and granted a Priority Review for Gilead's New Drug Application (NDA) for marketing approval of ambrisentan (5 mg and 10 mg) for the once-daily treatment of PAH. The FDA has established a target review date, under the Prescription Drug User Fee Act (PDUFA), of June 18, 2007.

As an investigational compound, ambrisentan has not yet been determined safe or efficacious in humans.

GlaxoSmithKline holds rights to commercialize ambrisentan for PAH in territories outside of the United States. A Marketing Authorisation Application (MAA) for ambrisentan was filed with the European Medicines Agency (EMEA) earlier this year.

About Pulmonary Arterial Hypertension

PAH is a debilitating disease characterized by constriction of the blood vessels in the lungs leading to high pulmonary arterial pressures. These high pressures make it difficult for the heart to pump blood through the lungs to be oxygenated. Patients with PAH suffer from shortness of breath as the heart struggles to pump against these high pressures, causing such patients to ultimately die of heart failure. PAH can occur with no kno
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:5/22/2015)... 2015  Research and Benchmarking firm, Best Practices, ... Affairs Roundtable on Thursday, May 28th from ... to discuss "Medical Affairs, Role in Health Economics ... Affairs Consortium provides Medical Affairs leaders with a ... they face. The consortium has developed a mechanism ...
(Date:5/22/2015)... 22 2015 /CNW/ - The Taskforce representing Canada,s ... all the hard work that the Minister and Health Canada ... This program recognizes the needs of the thalidomide survivors, and ... a year, tax free, with annual adjustments for inflation. ... annual payments of $100,000 based on the severity of their ...
(Date:5/22/2015)... May 22, 2015  Amgen (NASDAQ: ... commenced termination of its participation in the ... (LON:AZN, STO:AZN and NYSE: AZN ).  ... development for patients with moderate-to-severe plaque psoriasis, ... was based on events of suicidal ideation ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... , OKLAHOMA CITY , July 12 For the ... to receive its prestigious R&D 100 Award.  Orthocare Innovations received this ... reporting the function of persons who have experienced lower limb loss, injury ... (Logo:   ...
... 12 Holon, the new standard for healthcare interoperability, ... , , ... the Holon Process Adaptive Interoperability Framework, Holon introduces a cost-effective ... solution by automating the collection and distribution of pharmacy information ...
Cached Medicine Technology:Orthocare Innovations Receives Prestigious R&D 100 Award for Novel Web-Based Rehabilitation Outcomes Assessment System 2Holon: The Process Adaptive Interoperability Framework 2
(Date:5/24/2015)... May 24, 2015 Women's Excellence ... hair loss. Although it is unclear about the etiology ... environmental factors such as metabolism, nutritional deficiencies, thyroid abnormalities ... offer a comprehensive approach to evaluating the metabolic, nutritional ... they can help patients find a cause for their ...
(Date:5/24/2015)... 2015 EnviroLeather™ by LDI, a ... – a classic, rugged leather grain with enhanced ... stains, including ink, to be easily removed. The ... for corporate, healthcare, hospitality and education environments. , ... goal of developing products that are more sustainable, ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
(Date:5/23/2015)... 23, 2015 On May 13, Nithyananda ... a youngster's yogic power learned through meditation and initiation ... in Bangalore, India. , Yogamaatha, a nine-year-old girl from ... high profile professionals attending the 2015 Business Advocacy Summit ... -- blindfolded. , In a demonstration that lasted ...
(Date:5/23/2015)... Parker, CO (PRWEB) May 23, 2015 On ... participated in MuckFest. The event was a 5k mud obstacle ... affects more than 2 million people worldwide, and the reason ... our community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. ... National Multiple Sclerosis Society.” , The event was not only ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... ST. LOUIS, June 5 Celebrities, from high-profile,athletes to ... products,including expensive energy drinks and even candy bars, are ... it is the nutrient fad of the,moment., Fleming ... on the market ranged from 40% all the way ...
... Diana Kirschner Explains the Psychology Behind It, NEW ... an estimated,$55.7 million for its opening weekend, beating out ... other romantic comedy has ever,opened with such a lucrative ... occurring," says Dr. Diana Kirschner, psychologist and,recurring relationship expert ...
... Expects FDA to Request Additional Safety Study Prior to ... Inc.,(Nasdaq: IDEV ) today announced that based on ... (FDA) regarding the NDA filing for,NEBIDO(R), the Company expects ... safety data prior to approving NEBIDO. The Company,currently believes ...
... risk of developing rheumatoid arthritis by up to 50%, ... of the Rheumatic Diseases. , The Scandinavian researchers base ... in two separate studies, which assessed environmental and genetic ... the participants (1650) had the disease and had been ...
... FALLS CHURCH, Va., June 4 CSC (NYSE: ... Dell Inc. (Nasdaq: DELL ) to design and,deploy ... and,complexity out of their information technology (IT) environment and ... help clients,simplify processes associated with IT and enhance innovation ...
... to Ensure Equitable Protections,for All Americans and Their ... America,s,Health (TFAH) issued the following statement on the ... Services(HHS) Draft Guidances to Assist in,Preparation for an ... government must do all it can to ensure ...
Cached Medicine News:Health News:The Vitamin B12 Craze - Super Nutrient or Super Hype? 2Health News:Why is the Sex & the City Movie a Mega-Blockbuster? 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 3Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 4Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 5Health News:Regular tipple may curb risk of rheumatoid arthritis 2Health News:CSC to Simplify IT From Desktop to Data Center 2Health News:Trust for America's Health on New HHS Influenza Pandemic Draft Guidance 2
... Another first for Linvatec! The EnVision ... experience and proprietary technology to ensure ... Linvatecs Shockflex prism system gives our ... protect their investment. With an integrated ...
... customized digital camera offers maximum ... video needs. With internal video ... to best meet your specific ... are interchangeable with autoclavable and ...
... 1-Chip Camera System provides easy-to-use features, auto ... scope. The camera head construction is based ... 14, Complete 1-Chip Camera System, International (GS ... Unit (CCU) with video cables , (GS ...
... 1-Chip Camera System provides easy-to-use features, auto ... scope. The camera head construction is based ... 12, Complete 1-Chip Camera System, International (GS9900-PAL) ... (CCU) with power cord and video cables ...
Medicine Products: